• Press Release

Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program

Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations.

  • New York, NY
  • (June 08, 2021)

Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New York City, has launched Elementa Labs, a virtual incubator program that aims to position health care and biotechnology startup companies for the next stage in their development.

The program empowers companies to strategically align with Mount Sinai, gaining access to subject matter experts in health care and the potential to advance their core technology platforms. Participating companies will work directly with a Mount Sinai champion who will facilitate navigation within the Health System and enable access to key stakeholders, resources, and know-how to advance product development.

“Elementa Labs will integrate Mount Sinai’s research and clinical expertise with the business and product development infrastructure of health care startup companies,” said Erik Lium, PhD, President of MSIP and Chief Commercial Innovation Officer of Mount Sinai Health System. “We look forward to engaging with entrepreneurs to bring health care innovations to the patient population.”

The first member of Elementa’s inaugural cohort is digital health company avoMD, which has launched a next-generation platform providing decision support for clinicians. The company will work with Mount Sinai to create a strategic path to conduct research, further validate studies, and surface the depth of clinical needs for their platform at a leading health care system.

“We are thrilled by the opportunity to enhance our platform and offerings by working with Mount Sinai, a global leader in education, cutting-edge research and innovation, and high-quality care,” said Laurence Coman, Chief Operating Officer and Co-Founder of avoMD. “Elementa Labs will help take avoMD to the next level.”

Companies interested in applying can visit the Elementa Labs web page for more information. For the first cohort, the rolling application process concludes on Thursday, September 30, 2021.

About Mount Sinai Innovation Partners (MSIP)
Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit www.ip.mountsinai.org or find MSIP on LinkedIn, Twitter, Facebook, Medium, and YouTube.

About avoMD
avoMD is building the next-gen platform for interactive clinical guidelines and decision support. Leading provider organizations use avoMD to digitize their clinical workflows and algorithms and put them in the hands of all of their providers instantly. The technology functions on a standalone basis via web and mobile apps, or can integrate into the EHR. In usability trials and live deployments, the software has been shown to dramatically increase clinical guideline usability and usage. Led by a team of physicians and informaticians from Harvard, Yale and Mount Sinai, avoMD has over 10 current hospital and urgent care partners including Children’s Minnesota, PM Pediatrics, and Samsung Medical Center.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.